Coexistence of Hashimoto's Thyroiditis in Differentiated Thyroid Cancer: Post-Operative Monitoring of Anti-Thyroglobulin Antibodies and Assessment of Treatment Response

Alessandra Donnici,Maria Mirabelli,Stefania Giuliano,Roberta Misiti,Vera Tocci,Marta Greco,Vincenzo Aiello,Francesco S. Brunetti,Eusebio Chiefari,Antonio Aversa,Daniela P. Foti,Antonio Brunetti
DOI: https://doi.org/10.3390/diagnostics14020166
IF: 3.6
2024-01-12
Diagnostics
Abstract:Introduction: Differentiated thyroid carcinoma (DTC) is frequently found in conjunction with autoimmune thyroid disorders, particularly Hashimoto's thyroiditis (HT). This study investigates the impact of coexisting HT on the persistence of an indeterminate response to therapy due to positive anti-thyroglobulin antibodies (AbTg), measured via competitive immunoassay, in a consecutive patient series from Calabria, Southern Italy. Methods: This retrospective longitudinal study analyzed 259 consecutive DTC patients managed at the Endocrinology Unit of Renato Dulbecco Hospital (Catanzaro, Italy) up to 2023. Patients with medullary and undifferentiated thyroid carcinoma, partial thyroidectomy, less than six months of post-operative monitoring, or missing clinical data were excluded. Demographic information, histological findings, initial tumor stage, and ATA risk category were collected. The response to therapy was assessed based on ATA guidelines. Results: Among the 259 patients, 29% had coexisting HT. Patients with HT exhibited distinct characteristics: a higher proportion of females (87.0% vs. 74.7%), a shorter post-operative monitoring duration (median 3 vs. 5 years), and a higher prevalence of papillary thyroid carcinoma (PTC) (97.4% vs. 86.3%). The tumor size, lymph node involvement, and distant metastasis were similar between the groups, with patients without HT having a higher incidence of extrathyroidal tumor extension. However, the initial TNM stage and ATA risk category did not differ significantly. At the six-month follow-up, HT patients showed a higher rate of indeterminate responses, primarily due to positive AbTg. After 12 months, the response categories aligned, with decreasing AbTg levels in the HT group. After 24 months, most patients with long-term follow-up demonstrated an excellent response to DTC therapy, irrespective of HT coexistence. Conclusions: While HT does not worsen DTC prognosis, it may result in indeterminate responses. AbTg measurements in the peri-operative period should be encouraged to facilitate post-operative monitoring, emphasizing the importance of using standardized assays. Further research in larger populations with extended follow-up is needed to comprehensively understand the HT-DTC relationship.
medicine, general & internal
What problem does this paper attempt to address?
The paper primarily explores the impact of the coexistence of Hashimoto’s Thyroiditis (HT) and Differentiated Thyroid Carcinoma (DTC) on treatment response, with a particular focus on the role of Anti-Thyroglobulin Antibodies (AbTg) in postoperative monitoring. ### Research Objectives - To investigate the impact of the coexistence of Hashimoto’s Thyroiditis and Differentiated Thyroid Carcinoma on long-term treatment response. - To evaluate the changes in postoperative Anti-Thyroglobulin Antibodies levels and their impact on the assessment of treatment response. ### Main Findings - Among the 259 DTC patients studied, 29% also had Hashimoto’s Thyroiditis. - Patients with Hashimoto’s Thyroiditis exhibited certain specific characteristics, such as a higher proportion of females, shorter postoperative monitoring time, and a higher incidence of Papillary Thyroid Carcinoma (PTC). - During the 6-month postoperative follow-up, patients with Hashimoto’s Thyroiditis showed a higher rate of indeterminate treatment response, which was mainly associated with positive AbTg. - Over time, by the 12-month postoperative mark, the difference in treatment response between the two groups decreased, and AbTg levels declined. - After 24 months of follow-up, most patients, regardless of the presence of Hashimoto’s Thyroiditis, showed a good response to DTC treatment. ### Conclusion - Although Hashimoto’s Thyroiditis may affect the assessment of treatment response, it does not seem to worsen the prognosis of DTC. - Preoperative and early postoperative monitoring of AbTg levels is crucial for guiding treatment decisions in DTC patients. - Further research is needed to fully understand the relationship between Hashimoto’s Thyroiditis and Differentiated Thyroid Carcinoma and to optimize clinical management strategies.